• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特定血浆神经酰胺与冠状动脉造影评估的冠状动脉狭窄严重程度之间的关系。

Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography.

机构信息

Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.

Division of Cardiology, "IRCCS Sacro Cuore - Don Calabria" Hospital, Negrar (VR), Italy.

出版信息

Diabetes Metab. 2020 Apr;46(2):150-157. doi: 10.1016/j.diabet.2019.07.006. Epub 2019 Aug 3.

DOI:10.1016/j.diabet.2019.07.006
PMID:31386900
Abstract

AIM

Recent prospective studies have identified distinct plasma ceramides as strong predictors of major adverse cardiovascular events in patients with established or suspected coronary artery disease (CAD). Currently, it is uncertain whether higher levels of distinct plasma ceramides are associated with greater angiographic severity of coronary-artery stenoses in this patient population.

METHODS

We measured six previously identified high-risk plasma ceramide species [Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/20:0), Cer(d18:1/22:0), Cer(d18:1/24:0) and Cer(d18:1/24:1)] in 167 consecutive patients with established or suspected CAD, who underwent urgent or elective coronary angiography.

RESULTS

Approximately 77% of patients had a significant stenosis (≥50%) in one or more of the main coronary arteries, the majority of whom (∼60%) had a significant stenosis in the left anterior descending (LAD) artery. Of the six measured plasma ceramides, higher levels of plasma Cer(d18:1/20:0) (adjusted-odds ratio 1.39, 95%CI 1.0-1.99), Cer(d18:1/22:0) (adjusted-odds ratio 1.57, 95%CI 1.08-2.29) and Cer(d18:1/24:0) (adjusted-odds ratio 1.59, 95%CI 1.08-2.32) were significantly associated with the presence of LAD stenosis≥50%, after adjustment for age, sex, smoking, pre-existing CAD, hypertension, diabetes, dyslipidaemia, lipid-lowering therapy, estimated glomerular filtration rate and plasma C-reactive protein levels. Almost identical results were found even after excluding patients (n=15) with acute ST-elevation myocardial infarction. Similar results were also found when patients were categorized according to the Gensini severity score.

CONCLUSION

Our cross-sectional study shows for the first time that higher levels of specific plasma ceramides are independently associated with a greater severity of coronary-artery stenoses in the LAD artery in patients who had suspected or established CAD.

摘要

目的

最近的前瞻性研究已经确定了不同的血浆神经酰胺作为已确诊或疑似冠心病(CAD)患者发生主要不良心血管事件的强有力预测因子。目前,尚不确定在这一患者群体中,不同的血浆神经酰胺水平是否与冠状动脉狭窄的血管造影严重程度更大相关。

方法

我们在 167 例已确诊或疑似 CAD 的连续患者中测量了 6 种先前确定的高风险血浆神经酰胺种类[Cer(d18:1/16:0)、Cer(d18:1/18:0)、Cer(d18:1/20:0)、Cer(d18:1/22:0)、Cer(d18:1/24:0)和 Cer(d18:1/24:1)],这些患者接受了紧急或选择性冠状动脉造影。

结果

约 77%的患者有一条或多条主要冠状动脉的显著狭窄(≥50%),其中大多数(约 60%)的左前降支(LAD)有显著狭窄。在测量的 6 种血浆神经酰胺中,较高的血浆 Cer(d18:1/20:0)(调整后比值比 1.39,95%CI 1.0-1.99)、Cer(d18:1/22:0)(调整后比值比 1.57,95%CI 1.08-2.29)和 Cer(d18:1/24:0)(调整后比值比 1.59,95%CI 1.08-2.32)水平与 LAD 狭窄≥50%显著相关,校正年龄、性别、吸烟、既往 CAD、高血压、糖尿病、血脂异常、降脂治疗、估计肾小球滤过率和血浆 C 反应蛋白水平后。即使排除了 15 例急性 ST 段抬高型心肌梗死患者(n=15),也得到了几乎相同的结果。当根据 Gensini 严重程度评分对患者进行分类时,也得到了类似的结果。

结论

我们的横断面研究首次表明,在疑似或确诊 CAD 的患者中,特定血浆神经酰胺水平较高与 LAD 动脉冠状动脉狭窄严重程度独立相关。

相似文献

1
Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography.特定血浆神经酰胺与冠状动脉造影评估的冠状动脉狭窄严重程度之间的关系。
Diabetes Metab. 2020 Apr;46(2):150-157. doi: 10.1016/j.diabet.2019.07.006. Epub 2019 Aug 3.
2
Association between ceramides and coronary artery stenosis in patients with coronary artery disease.在冠心病患者中,神经酰胺与冠状动脉狭窄之间存在关联。
Lipids Health Dis. 2020 Jun 25;19(1):151. doi: 10.1186/s12944-020-01329-0.
3
Association between plasma ceramides and inducible myocardial ischemia in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy.血浆神经酰胺与已确诊或疑似冠心病患者心肌灌注闪烁显像中可诱导性心肌缺血之间的相关性。
Metabolism. 2018 Aug;85:305-312. doi: 10.1016/j.metabol.2018.05.006. Epub 2018 May 16.
4
Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.血浆神经酰胺可预测稳定型冠状动脉疾病和急性冠状动脉综合征患者的心血管死亡,且独立于低密度脂蛋白胆固醇。
Eur Heart J. 2016 Jul 1;37(25):1967-76. doi: 10.1093/eurheartj/ehw148. Epub 2016 Apr 28.
5
Association of Plasma Ceramides With Myocardial Perfusion in Patients With Coronary Artery Disease Undergoing Stress Myocardial Perfusion Scintigraphy.血浆神经酰胺与冠状动脉疾病患者应激心肌灌注显像心肌灌注的相关性。
Arterioscler Thromb Vasc Biol. 2018 Dec;38(12):2854-2861. doi: 10.1161/ATVBAHA.118.311927.
6
Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease.血浆神经酰胺水平升高与缺血性心脏病和非缺血性心脏病患者慢性肾脏病的关系。
Diabetes Metab. 2021 Feb;47(1):101152. doi: 10.1016/j.diabet.2020.03.003. Epub 2020 Apr 10.
7
Association between specific plasma ceramides and high-sensitivity C-reactive protein levels in postmenopausal women with type 2 diabetes.绝经后 2 型糖尿病妇女特定血浆神经酰胺与高敏 C 反应蛋白水平的关系。
Diabetes Metab. 2020 Sep;46(4):326-330. doi: 10.1016/j.diabet.2019.05.008. Epub 2019 Jun 8.
8
Plasma Ceramides.血浆神经酰胺。
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1933-1939. doi: 10.1161/ATVBAHA.118.311199.
9
Plasma ceramides are associated with coronary atherosclerotic burden in patients with ST-segment elevation myocardial infarction.血浆神经酰胺与ST段抬高型心肌梗死患者的冠状动脉粥样硬化负担相关。
Int J Cardiol. 2020 Dec 1;320:155-160. doi: 10.1016/j.ijcard.2020.08.010. Epub 2020 Aug 12.
10
Ceramide stearic to palmitic acid ratio predicts incident diabetes.神经酰胺硬脂酸对棕榈酸的比值可预测糖尿病的发生。
Diabetologia. 2018 Jun;61(6):1424-1434. doi: 10.1007/s00125-018-4590-6. Epub 2018 Mar 15.

引用本文的文献

1
Machine Learning based Model Reveals the Metabolites Involved in Coronary Artery Disease.基于机器学习的模型揭示了冠状动脉疾病中涉及的代谢物。
Biomed Eng Comput Biol. 2025 Jul 8;16:11795972251352014. doi: 10.1177/11795972251352014. eCollection 2025.
2
The association between circulating palmitic acid levels and risk of premature coronary artery disease in Chinese patients: a case-control study.中国患者循环棕榈酸水平与早发冠状动脉疾病风险的关联:一项病例对照研究。
BMC Cardiovasc Disord. 2025 May 28;25(1):412. doi: 10.1186/s12872-025-04873-8.
3
Deciphering Acute Coronary Syndromes Pathobiology Through Proteomics.
通过蛋白质组学解读急性冠脉综合征的病理生物学
J Cardiovasc Dev Dis. 2025 May 15;12(5):188. doi: 10.3390/jcdd12050188.
4
Correlation Between Coronary Arterial Dominance and the Degree of Coronary Artery Disease Using Computed Tomography Angiography.使用计算机断层扫描血管造影术评估冠状动脉优势与冠状动脉疾病程度之间的相关性
J Multidiscip Healthc. 2025 Mar 30;18:1827-1844. doi: 10.2147/JMDH.S514510. eCollection 2025.
5
Cardiac dysfunction and altered gene expression in acid ceramidase-deficient mice.酸性神经酰胺酶缺陷小鼠的心脏功能障碍与基因表达改变
Am J Physiol Heart Circ Physiol. 2025 Jan 1;328(1):H141-H156. doi: 10.1152/ajpheart.00289.2024. Epub 2024 Dec 12.
6
The Essence of Lipoproteins in Cardiovascular Health and Diseases Treated by Photodynamic Therapy.光动力疗法治疗心血管疾病中脂蛋白的本质
Biomedicines. 2024 Apr 26;12(5):961. doi: 10.3390/biomedicines12050961.
7
Structure and mechanism of a eukaryotic ceramide synthase complex.真核神经酰胺合酶复合物的结构与机制。
EMBO J. 2023 Dec 11;42(24):e114889. doi: 10.15252/embj.2023114889. Epub 2023 Nov 13.
8
Searching for Atherosclerosis Biomarkers by Proteomics: A Focus on Lesion Pathogenesis and Vulnerability.通过蛋白质组学寻找动脉粥样硬化生物标志物:关注病变发病机制和易损性。
Int J Mol Sci. 2023 Oct 14;24(20):15175. doi: 10.3390/ijms242015175.
9
Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 Diabetes.神经酰胺可作为长期 1 型糖尿病患者未来心血管事件和全因死亡率的风险标志物。
Diabetes. 2023 Oct 1;72(10):1493-1501. doi: 10.2337/db23-0052.
10
Sphingosine-1-Phosphate Signaling in Cardiovascular Diseases.鞘氨醇-1-磷酸信号通路在心血管疾病中的作用
Biomolecules. 2023 May 11;13(5):818. doi: 10.3390/biom13050818.